亚司匹林改善了高胆固醇血预孕的子宫动脉功能
Amanda A de Oliveira1,2, Floor Spaans1,2, Murilo E Graton1,2
1Department of Obstetrics and Gynecology (A.A.d.O., F.S., M.E.G., R.K., A.Q., C.-L.M.C., S.T.D.), University of Alberta, Edmonton, Canada.
Hypertension (Dallas, Tex. : 1979)
|February 12, 2025
概括
低剂量阿司匹林在高胆固醇和孕产前的怀孕中改善了子宫动脉功能,通过抑制类似收费受体4/类似莱克的oxLDL受体-1/前列腺素H合成酶1通路.
科学领域:
- 产科和妇科 产科和妇科
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 妊娠中高胆固醇 (HC-PE) 增加了子宫前风险,子宫动脉功能受损与收费类受体4 (TLR4) /前列腺素H合成酶1 (PGHS1) 途径有关.
- 氧化低密度脂蛋白 (oxLDL) 水平在HC-PE中增加,可能会激活TLR4和拾尸体受体LOX-1 (乳素类oxLDL受体-1),但这仍未得到证实.
研究的目的:
- 为了研究低剂量阿司匹林对子宫动脉功能在HC-PE的老鼠模型的影响.
- 确定阿司匹林是否调节HC-PE中的TLR4/PGHS1和oxLDL/TLR4/LOX-1通路.
主要方法:
- 通过使用高胆固醇饮食,建立了HC-PE的老鼠模型.
- 在怀孕期间,老鼠接受了安慰剂或低剂量阿司匹林.
- 评估了子宫动脉功能,血流,胎盘体重和分子通路激活.
主要成果:
- 低剂量阿司匹林在HC-PE大鼠中降低了子宫动脉血流速度升高和胎盘体重.
- 阿司匹林在HC-PE子宫动脉中使受损的内皮依赖血管扩张正常化.
- 抑制TLR4,PGHS1或LOX-1在体外也改善了血管扩张;oxLDL暴露进一步损害了血管扩张,部分是通过TLR4/LOX-1,阿司匹林阻断了这种作用.
结论:
- 低剂量阿司匹林在HC-PE中有效改善子宫动脉内皮功能.
- 阿司匹林的有益作用很可能是通过抑制TLR4/LOX-1/PGHS1通路来调解的.
更多相关视频
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
328
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
328
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Adrenergic Antagonists: ɑ and β-Receptor Blockers
404
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
404
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145


